LMO2 and gene therapy for severe combined immunodeficiency

N Engl J Med. 2004 Jun 10;350(24):2526-7; author reply 2526-7. doi: 10.1056/NEJM200406103502422.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Age Factors
  • Gene Expression Regulation
  • Genetic Diseases, X-Linked / genetics
  • Genetic Diseases, X-Linked / therapy
  • Genetic Therapy*
  • Humans
  • Interleukin-2 / metabolism
  • Oncogenes*
  • Receptors, Interleukin-2 / genetics
  • Receptors, Interleukin-2 / metabolism
  • Severe Combined Immunodeficiency / genetics*
  • Severe Combined Immunodeficiency / therapy
  • T-Lymphocytes / physiology*
  • Virus Activation

Substances

  • Interleukin-2
  • Receptors, Interleukin-2